- Trials with a EudraCT protocol (60)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
60 result(s) found for: Anamnesis.
Displaying page 1 of 3.
| EudraCT Number: 2006-005304-14 | Sponsor Protocol Number: AL0205PR | Start Date*: 2007-01-09 | |||||||||||
| Sponsor Name:Allergopharma Joachim Ganzer KG | |||||||||||||
| Full Title: Design of optimally-diagnostic skin test solutions for diagnosis of sensitisation to a 6-grass pollen mixture, house dust mite (Dermatophagoides pteronyssinus), birch pollen and mugwort pollen and ... | |||||||||||||
| Medical condition: Sensitisation to one or more allergens of 6-grass pollen mixture (Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior), house dust mite (Dermatophago... | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-000865-13 | Sponsor Protocol Number: PMLD17102005 | Start Date*: 2006-04-17 |
| Sponsor Name:Univ.Clinic of Dermatology | ||
| Full Title: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg... | ||
| Medical condition: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-004579-37 | Sponsor Protocol Number: MZ12-PCP-PalenicekTomas-A | Start Date*: 2014-06-18 |
| Sponsor Name:National Institute of Mental Health | ||
| Full Title: Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI | ||
| Medical condition: Inclusion criteria: a) Men and women at age between 28 and 65 years b) healthy volunteers with negative psychiatric history (severe mental illnesses that meet the criteria of ICD 10 F0.X - F99.X) ... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004845-32 | Sponsor Protocol Number: HAVCARD-05/01 | Start Date*: 2006-05-09 |
| Sponsor Name:Soria Natural, S.A. | ||
| Full Title: ESTUDIO FASE II ABIERTO, COMPARATIVO, CRUZADO, SOBRE EFECTO ANTIAGREGANTE PLAQUETARIO DE CRATAESOR® Y ASPIRINA EN VOLUNTARIOS SANOS. | ||
| Medical condition: Agregación plaquetaria | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-000795-24 | Sponsor Protocol Number: WIL-18 | Start Date*: 2008-10-06 |
| Sponsor Name:Octapharma AG | ||
| Full Title: Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate | ||
| Medical condition: von Willebrand disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-003703-21 | Sponsor Protocol Number: 5802003 | Start Date*: 2005-01-28 |
| Sponsor Name:Semmelweis University | ||
| Full Title: The role of hyperhomocysteinemia in the genesis of atherothrombotic vascular disease | ||
| Medical condition: Established cardiovascular disease with elevated levels of homocystein | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004463-30 | Sponsor Protocol Number: ATS K015 | Start Date*: 2005-06-22 |
| Sponsor Name:Takeda Pharma GmbH | ||
| Full Title: Effects of Pioglitazone in Combination with Atorvastatin in Comparison to Atorvastatin treatment alone on Intima-Media Thickness in patients at Risk for Vascular Complications | ||
| Medical condition: Patients at risk for vascular complications (cardiovascular anamnesis, hypertension, hypercholesterolemia) and a carotid intima media thickness >= 0.8 mm at least at one side will be eligible for t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004872-47 | Sponsor Protocol Number: NSAID2015 | Start Date*: 2015-07-20 |
| Sponsor Name:Karolinska Institutet, Department of Laboratory Medicine, Clinical Physiology C1:82,Karolinska Univ. Hosp., Huddinge | ||
| Full Title: The effects of COX-inhibiting drugs on skeletal muscle adaptations to resistance exercise in healthy adults. | ||
| Medical condition: Human skeletal muscle adaptations to resistance exercise (non-disease related). | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001912-38 | Sponsor Protocol Number: ACR-CMOD / 2005-2 | Start Date*: 2006-01-11 |
| Sponsor Name:ACROSS | ||
| Full Title: PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE Estudio fase II de la combinación de gemcitabina... | ||
| Medical condition: METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-002023-32 | Sponsor Protocol Number: Niaspan | Start Date*: 2007-10-05 |
| Sponsor Name:Charité - Universitätsmedizin Berlin | ||
| Full Title: Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia | ||
| Medical condition: Patients in this study do have symptomes like dyspnea, reduced maximum stress and do have a weakness feeling. We are analysing the endothelial function via the FMD-methode: Before and after a Niasp... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002210-13 | Sponsor Protocol Number: STARC210421 | Start Date*: 2022-01-17 | |||||||||||
| Sponsor Name:The department of cardiac, thoracic and vascular surgery - Odense University Hospital | |||||||||||||
| Full Title: Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacement and the influence of HMG-CoA reductase inhibitors | |||||||||||||
| Medical condition: Trial 2: Condition under investigation: Postoperative atrial fibrillation after surgical aortic valve replacement. In patients no prior usage of statins: 14 days prior surgery to 30days after - Ato... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001966-40 | Sponsor Protocol Number: CD001 | Start Date*: 2014-01-27 | ||||||||||||||||
| Sponsor Name:Companion Diagnostics BV | ||||||||||||||||||
| Full Title: A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify an... | ||||||||||||||||||
| Medical condition: Hypoactive Sexual Desire Disorder/SSRI-induced sexual dysfunction | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2005-002574-29 | Sponsor Protocol Number: 77550 | Start Date*: 2005-08-02 |
| Sponsor Name:Santen Oy | ||
| Full Title: Pharmacodynamics of tafluprost 0.0015% eye drops: a comparison between the preserved and unpreserved formulation in patients with open-angle glaucoma or ocular hypertension. | ||
| Medical condition: Open angle glaucoma or ocular hypertension | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-001457-50 | Sponsor Protocol Number: SIL-TH-01 | Start Date*: 2012-05-23 |
| Sponsor Name:fUNDACIÓN iNVESTIGACIÓN HOSPITAL RAMÓN Y CAJAL | ||
| Full Title: Study on the effect of intravenous silimaryn in the perioperative period of liver transplantation (before, during and after) for the prevention and prognosis of hepatitis C virus reinfection of the... | ||
| Medical condition: Patients transplanted for chronic liver disease or hepatocarcinoma relating to C virus being replicated at the time of the OLT (orthotopic liver transplantation). | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000562-38 | Sponsor Protocol Number: BCBe/03/Pan-CPI/002 | Start Date*: 2010-04-20 | |||||||||||
| Sponsor Name:Berlin-Chemie AG | |||||||||||||
| Full Title: RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WI... | |||||||||||||
| Medical condition: The purpose of this trial is to evaluate the clinical efficacy and safety of a gastro-resistant film-coated tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003090-26 | Sponsor Protocol Number: 110401 | Start Date*: 2013-03-25 |
| Sponsor Name:TECNIMEDE ? SOCIEDADE TÉCNICO MEDICINAL S.A. | ||
| Full Title: STUDY TO EVALUATE THE PROPORTIONALITY OF 3 ORAL DOSES OF PIRLINDOLE IN HEALTHY VOLUNTEERS. | ||
| Medical condition: Not applicable (including healthy volunteers). | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003770-32 | Sponsor Protocol Number: CLR_14_05 | Start Date*: 2016-01-04 |
| Sponsor Name:Sun Pharma Advanced Research Company | ||
| Full Title: A Randomized, Double-Blind, Four Treatment, Four period, Crossover Study, with Placebo, Tizanidine Immediate Release and Diphenhydramine to Study the Effect of Tizanidine Extended Release on Simula... | ||
| Medical condition: healthy volunteers (acute musculoskeletal pain) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001146-29 | Sponsor Protocol Number: 1 | Start Date*: 2016-01-12 |
| Sponsor Name:Hospital Central de la Defensa | ||
| Full Title: Selective local anesthesia versus a combined medication injection with corticosteroids in degenerartive spine | ||
| Medical condition: Degenerative spine pain when there are no indications for surgical treatment | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-005523-27 | Sponsor Protocol Number: CIRROXABAN | Start Date*: 2015-07-30 |
| Sponsor Name:INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS) | ||
| Full Title: Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis | ||
| Medical condition: Liver cirrhosis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
| Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
| Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
| Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
